Status:
ACTIVE_NOT_RECRUITING
Imagery as Biomarker of Gout
Lead Sponsor:
Lille Catholic University
Collaborating Sponsors:
Auckland University
Conditions:
Hyperuricemia
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
The objective of this study is to determine whether MSU crystal deposits visualized on ultrasound and/or DECT are associated with the development of symptomatic gout (according to ACR 2015 / EULAR cri...
Detailed Description
Cross-sectional studies have shown that 17% to 86% of people with apparently asymptomatic hyperuricemia have ultrasound evidence of monosodium urate (MSU) crystal deposition. These observations sugges...
Eligibility Criteria
Inclusion
- Serum urate level ≥ 80 mg/L on inclusion,
- No current or previous clinical symptoms of gout (including clinically apparent flares or tophus),
- Between 18 and 80 years old,
- Able to give informed consent.
Exclusion
- GFR (glomerular filtration rate) \<30 ml / min / 1.73 m² or dialysis,
- Serious illness with a poor prognosis of less than 5 years,
- Autoimmune inflammatory arthritis,
- Change of geographical area within 5 years,
- Previous analysis of synovial fluid showing crystals of MSU,
- Presence of subcutaneous tophi,
- Taking a hypouricaemic treatment (allopurinol, probenecid, benzbromarone, febuxostat, lesinurad), canakinumab, anakinra or colchicine,
- Uricemia observed only after an acute decompensation of comorbidity
- Pregnant or breastfeeding women
Key Trial Info
Start Date :
September 9 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 9 2029
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT05434858
Start Date
September 9 2022
End Date
September 9 2029
Last Update
September 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lille Catholic Hospital
Lille, Hauts-de-France, France, 59462